Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

275 results about "Cell response" patented technology

Cellular response. The binding of chemical signals to their corresponding receptors induces events within the cell that ultimately change its behaviour. The nature of these intracellular events differs according to the type of receptor. Also, the same chemical signal can trigger different responses in different types of cell.

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and / or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.
Owner:SELECTA BIOSCI

Redirection of cellular immunity by protein tyrosine kinase chimeras

InactiveUS7320787B2Facilitates specific recognitionFacilitates destructionBiocidePeptide/protein ingredientsDna encodingProtein-Tyrosine Kinases
Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are cells which express the chimeric receptors and DNA encoding the chimeric receptors.
Owner:THE GENERAL HOSPITAL CORP

Method and apparatus for visual neural stimulation

Existing epiretinal implants for the blind are designed to electrically stimulate large groups of surviving retinal neurons using a small number of electrodes with diameters of several hundred μm. To increase the spatial resolution of artificial sight, electrodes much smaller than those currently in use are desirable. In this study we stimulated and recorded ganglion cells in isolated pieces of rat, guinea pig, and monkey retina. We utilized micro-fabricated hexagonal arrays of 61 platinum disk electrodes with diameters between 6 and 25 μm, spaced 60 μm apart. Charge-balanced current pulses evoked one or two spikes at latencies as short as 0.2 ms, and typically only one or a few recorded ganglion cells were stimulated. Application of several synaptic blockers did not abolish the evoked responses, implying direct activation of ganglion cells. Threshold charge densities were typically below 0.1 mC / cm2 for a pulse duration of 100 μs, corresponding to charge thresholds of less than 100 pC. Stimulation remained effective after several hours and at high frequencies. To demonstrate that closely spaced electrodes can elicit independent ganglion cell responses, we utilized the multi-electrode array to stimulate several nearby ganglion cells simultaneously. From these data we conclude that electrical stimulation of mammalian retina with small-diameter electrode arrays is achievable and can provide high temporal and spatial precision at low charge densities. We review previous epiretinal stimulation studies and discuss our results in the context of 32 other publications, comparing threshold parameters and safety limits.
Owner:SALK INST FOR BIOLOGICAL STUDIES +1

Exendin improves β-cell response in subjects with impaired glucose tolerance

InactiveUS7265087B1Restore responseLowering plasma insulin levelPeptide/protein ingredientsMetabolism disorderCell sensitivityGlucagon-like peptide-1
A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1, and a pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic β-cell sensitivity to blood glucose levels in a human with IGT. Also, a method for improving the pattern of insulin secretory responses in a human with IGT by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
Owner:ASTRAZENECA PHARMA LP

Human immune therapies using a cd27 agonist alone or in combination with other immune modulators

InactiveUS20130336976A1Promotes strong expression of 4-1BBImprove responseAntibacterial agentsAntimycoticsIMMUNE STIMULANTSCD8
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Owner:UNIV OF SOUTHAMPTON

Method and Apparatus for Visual Neural Stimulation

Existing epiretinal implants for the blind are designed to electrically stimulate large groups of surviving retinal neurons using a small number of electrodes with diameters of several hundred μm. To increase the spatial resolution of artificial sight, electrodes much smaller than those currently in use are desirable. In this study we stimulated and recorded ganglion cells in isolated pieces of rat, guinea pig, and monkey retina. We utilized micro-fabricated hexagonal arrays of 61 platinum disk electrodes with diameters between 6 and 25 μm, spaced 60 μm apart. Charge-balanced current pulses evoked one or two spikes at latencies as short as 0.2 ms, and typically only one or a few recorded ganglion cells were stimulated. Application of several synaptic blockers did not abolish the evoked responses, implying direct activation of ganglion cells. Threshold charge densities were typically below 0.1 mC / cm2 for a pulse duration of 100 μs, corresponding to charge thresholds of less than 100 pC. Stimulation remained effective after several hours and at high frequencies. To demonstrate that closely spaced electrodes can elicit independent ganglion cell responses, we utilized the multi-electrode array to stimulate several nearby ganglion cells simultaneously. From these data we conclude that electrical stimulation of mammalian retina with small-diameter electrode arrays is achievable and can provide high temporal and spatial precision at low charge densities. We review previous epiretinal stimulation studies and discuss our results in the context of 32 other publications, comparing threshold parameters and safety limits.
Owner:SECOND SIGHT MEDICAL PRODS +1

Anti-il13 receptor alpha1 neutralizing antibody

A novel anti-IL13 receptor α1 antibody having an activity of inhibiting a cell response by IL13, in particular, having an activity of inhibiting the cell response by IL13 but not inhibiting the cell response by IL4, a characteristic amino acid sequence in a variable region thereof, and a method of detecting IL13 receptor α1 in a sample using the same are provided.
Owner:MOCHIDA PHARM CO LTD

Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients

InactiveUS7094405B1High titerHigh titer of neutralizing antibodyPeptide/protein ingredientsAntibody mimetics/scaffoldsV3 loopT helper cell
Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the Dd class I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.
Owner:US DEPT OF HEALTH & HUMAN SERVICES

Cd47 partal peptdie and anti-shps-1 monoclonal antibody

A CD47 partial peptide which has an amino acid sequence constituting an extracellular region having an immunoglobulin-like structure of a CD47 protein, which is specifically bound to an N-terminal immunoglobulin-like structure of a dephosphorylation substrate protein SHPS-1 of an SH2 domain-containing protein, and which can act on a function of cell response mediated by SHPS-1, and an anti-SHPS-1 monoclonal antibody.
Owner:GUNMA UNIVERSITY

Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.
Owner:KUROS US LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products